TRPHARM is actively looking to develop and manufacture value-adding innovative treatments. Our goal is to provide medicine to patients both in Turkey and internationally, focusing on treatments in oncology, virology, and inflammatory and rare diseases.
Our partnership strategy is based on a long-term perspective. To actualize our goals we begin by fulfilling obligations in a timely manner, effective and clear communication in each stage, realizing the commitments and to win together. To talk about cooperation opportunities and to get further information about TRPHARM, please send an e-mail to email@example.com
OUR BUSINESS DEVELOPMENT MODEL
A large part of our success can also be measured by our partner’s strengths. We look for partners that have the same values as we do, loyalty, honest, radical transparency, and an urge to change the future.
TRPHARM, R-Pharm’s sole licensor for Turkey, Africa, Middle East and CIS regions.
TRPHARM is sole licensor of Remimazolam for Turkey & MENA.
TRPHARM is sole licensor of nemonoxacin for Turkey.
TRPHARM is sole licensor of SCY078 for Turkey & MENA.
TRPHARM is sole licensor of Iguratimod for Turkey & MENA.
TRPHARM is sole licensor of Polmacoxib for Turkey & MENA.
Dr. Reddy’s Laboratories
TRPHARM is strategic collaboration partner of DRL biosimilars in Turkey.
Sigma Tau Rare Disease
TRPHARM has exclusive commercialization rights of orphan product for Turkey.
INVESTMENT IN OUR GLOBAL FOOTPRINT
Our partnership with R-pharm has allowed us to extend our reach to all major continents across the globe. To achieve our global expansion plans together our business activities include exporting goods, licensing, forming strategic partnerships, acquiring businesses and building new facilities.